أعضاء هيئة التدريس - جامعة بنها
Left Gastric Artery Embolization in Obese, Prediabetic Patients: A Pilot Study
• 2019
معلومات البحث
المؤلفون
Mohamed M.A. Zaitoun, MD, Mohammad Abd Alkhalik Basha, MD,
Farouk Hassan, MD, Saeed Bakry Elsayed, MD, Alaa A. Farag, MD,
Mahmoud Amer, MD, Sameh Abdelaziz Aly, MD, and Nahla Zaitoun, MD
الكلمات المفتاحية
Not Available
المجلة العلمية
Not Available
الناشر
Not Available
المجلد
Not Available
العدد
Not Available
الصفحات
Not Available
publication.type
International
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
Purpose: To evaluate the effect of left gastric artery embolization (LGAE) on glycated hemoglobin (HbA1c) in a prospective obese,
prediabetic cohort.
Materials and Methods: This prospective pilot study included 10 obese, prediabetic patients (7 females and 3 males; mean age 37.5
± 8.8 years; range 28–51 years) admitted to the Interventional Radiology Unit between January 2017 and June 2018 for LGAE for
weight reduction. The main inclusion criteria were body mass index (BMI) >30 kg/m2 and HbA1c ranging from 5.7 to 6.4. Body
weight, BMI, and HbA1c were assessed for each patient preprocedure and at 6 months postprocedure. Statistical analysis was performed
using a paired sample t test.
Results: The baseline mean body weight, BMI, and HbA1c were 107.4 ± 12.8 kg, 37.4 ± 3.3 kg/m2, and 6 ± 0.2, respectively.
Concerning complications, no serious adverse events were detected. Six months after the procedure, the mean body weight and BMI
significantly decreased to 98 ± 11.6 kg and 34.1 ± 3 kg/m2, respectively (P < .0001). A paired sample t test showed a significant
reduction in HbA1c from pre- to postprocedure (6.1 ± 0.2 preprocedure vs 4.7 ± 0.6 postprocedure, P < .0001). The mean percent
reductions in body weight, BMI, and HbA1c were 8.9% ± 1.2, 8.8% ± 1, and 21.4% ± 8.9, respectively. A statistically significant
positive correlation was found between BMI and HbA1c after the procedure (r ¼ 0.91, P ¼ .0002).
Conclusions: LGAE is well tolerated and leads to clinically significant decreases in weight and HbA1c in obese, prediabetic patients.
prediabetic cohort.
Materials and Methods: This prospective pilot study included 10 obese, prediabetic patients (7 females and 3 males; mean age 37.5
± 8.8 years; range 28–51 years) admitted to the Interventional Radiology Unit between January 2017 and June 2018 for LGAE for
weight reduction. The main inclusion criteria were body mass index (BMI) >30 kg/m2 and HbA1c ranging from 5.7 to 6.4. Body
weight, BMI, and HbA1c were assessed for each patient preprocedure and at 6 months postprocedure. Statistical analysis was performed
using a paired sample t test.
Results: The baseline mean body weight, BMI, and HbA1c were 107.4 ± 12.8 kg, 37.4 ± 3.3 kg/m2, and 6 ± 0.2, respectively.
Concerning complications, no serious adverse events were detected. Six months after the procedure, the mean body weight and BMI
significantly decreased to 98 ± 11.6 kg and 34.1 ± 3 kg/m2, respectively (P < .0001). A paired sample t test showed a significant
reduction in HbA1c from pre- to postprocedure (6.1 ± 0.2 preprocedure vs 4.7 ± 0.6 postprocedure, P < .0001). The mean percent
reductions in body weight, BMI, and HbA1c were 8.9% ± 1.2, 8.8% ± 1, and 21.4% ± 8.9, respectively. A statistically significant
positive correlation was found between BMI and HbA1c after the procedure (r ¼ 0.91, P ¼ .0002).
Conclusions: LGAE is well tolerated and leads to clinically significant decreases in weight and HbA1c in obese, prediabetic patients.